5Dingemanse J, Jorga KM, Schmitt M, et al. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans.Clin Pharmacol Ther, 1995, May,57(5):50
6Kurth MC, Adler CH, Hilaire MS, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology, 1997,48(1):81～87
7Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. Neurology, 1998,50(5 Suppl 5):S46～53
8Roberts JW, Cora-Locatelli G, Bravi D, et al. Catechol-O-methyltransferase in hibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology,1993,43(12):2685～2688
9Yamamoto M, Yokochi M, Kuno S, et al. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson's disease. J Neural Transm, 1997,104(2-3):229～236
10Rajput AH, Martin W, Saint-Hilaire MH . Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology, 1997,49(4):1066～1071
二级参考文献1
1K. Haasio,L. Sopanen,L. Vaalavirta,I.-B. Lindén,E. H. Heinonen. Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat[J] 2001,Journal of Neural Transmission(1):79～91
